AstraZeneca Out-licenses US Rights for its COPD Drugs to Circassia
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)
Published: 22 Apr-2017
DOI: 10.3833/pdr.v2017.i4.2240 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca (AZ) has divested the US rights to two of its chronic obstructive pulmonary disease (COPD) drugs to Circassia in a deal worth up to US$300 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS